

# A cross-sectional study of clinical thrombotic risk factors in patients with antiphospholipid syndrome

British Journal of Rheumatology

41, 924-929

DOI: [10.1093/rheumatology/41.8.924](https://doi.org/10.1093/rheumatology/41.8.924)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: A review of the literature and management strategies. <i>Current Rheumatology Reports</i> , 2002, 4, 379-386.	4.7	17
2	Antiphospholipid antibody syndrome. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 127-136.	0.9	5
3	Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et al.. <i>Clinical Rheumatology</i> , 2003, 22, 493-493.	2.2	0
4	New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations. <i>Arthritis and Rheumatism</i> , 2003, 48, 3004-3008.	6.7	34
5	Actualizaci3n del s3ndrome antifosfolip3dico. <i>Medicina Cl3nica</i> , 2003, 121, 459-471.	0.6	2
6	Risk factors for thrombosis in pregnancy. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 197-210.	1.7	20
7	Prophylaxis of the antiphospholipid syndrome: a consensus report. <i>Lupus</i> , 2003, 12, 499-503.	1.6	95
8	Cardiac Involvement in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, 1, 213-225.	0.1	2
9	Letter to the Editor. <i>Lupus</i> , 2004, 13, 554-554.	1.6	1
10	Hormones and pregnancy: thromboembolic risks for women. <i>British Journal of Haematology</i> , 2004, 126, 443-454.	2.5	76
11	Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2004, 43, 28-36.	1.9	139
12	What is antiphospholipid syndrome?. <i>Current Rheumatology Reports</i> , 2004, 6, 451-457.	4.7	42
13	Treatment of the antiphospholipid antibody syndrome. <i>Current Rheumatology Reports</i> , 2004, 6, 463-468.	4.7	0
14	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. <i>Arthritis and Rheumatism</i> , 2004, 50, 3177-3186.	6.7	62
15	How much warfarin is enough in APS related thrombosis?. <i>Thrombosis Research</i> , 2004, 114, 435-442.	1.7	13
16	Peripheral vascular disease in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2004, 114, 509-519.	1.7	26
18	Antiphospholipid Antibody Syndrome (APS) Presenting as Splenic Thrombosis and Acute Acalculous Cholecystitis. <i>Acta Chirurgica Belgica</i> , 2004, 104, 733-735.	0.4	6
19	Prenatal transfer of anticardiolipin antibodies associated with fatal neonatal aortic thrombosis. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 175-176.	1.0	6

#	ARTICLE	IF	CITATIONS
20	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	1.6	72
21	Antiphospholipid Antibodies as a Cause of Pulmonary Capillaritis and Diffuse Alveolar Hemorrhage: A Case Series and Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 154-165.	3.4	95
22	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. <i>Arthritis and Rheumatism</i> , 2005, 52, 1473-1480.	6.7	324
23	Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. <i>Canadian Journal of Anaesthesia</i> , 2005, 52, 143-147.	1.6	13
24	Antimalarials. , 2005, , 347-372.		0
25	Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. <i>Lupus</i> , 2005, 14, 953-958.	1.6	11
26	Thrombosis and the Antiphospholipid Syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 462-468.	2.5	41
28	Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. <i>Immunobiology</i> , 2005, 210, 755-760.	1.9	12
29	New Treatments for Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 129-148.	1.9	32
30	Prevalence of antiphospholipid antibodies in patients with neurological symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 135-142.	1.4	30
31	Antiphospholipid Syndrome and Thrombosis. <i>Clinical Obstetrics and Gynecology</i> , 2006, 49, 861-874.	1.1	18
32	Antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2006, 18, 242-248.	4.3	25
33	Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 584-593.	1.5	36
34	The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 79-83.	2.1	21
35	Anticoagulation Strategies for Treatment of Ischemic Stroke and Antiphospholipid Syndrome: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2006, 26, 1518-1525.	2.6	5
36	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. <i>Future Rheumatology</i> , 2006, 1, 225-233.	0.2	8
37	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 577-583.	1.6	351
38	Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. <i>Lupus</i> , 2007, 16, 782-787.	1.6	32

#	ARTICLE	IF	CITATIONS
39	How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. <i>Blood</i> , 2007, 110, 3122-3127.	1.4	33
40	Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 810-816.	1.6	71
41	New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. <i>Expert Reviews in Molecular Medicine</i> , 2007, 9, 1-15.	3.9	31
42	Antiphospholipid syndrome in children: review of pathogenesis, diagnosis and treatment. <i>Future Rheumatology</i> , 2007, 2, 203-211.	0.2	0
43	The Antiphospholipid Syndrome. <i>Seminars in Nephrology</i> , 2007, 27, 35-46.	1.6	39
44	Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. <i>Scandinavian Journal of Rheumatology</i> , 2007, 36, 198-205.	1.1	32
45	Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature). <i>Journal of Thrombosis and Haemostasis</i> , 2007, 7, 1183-1188.	1.6	13
46	Tobacco smoking and autoimmune rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 707-715.	3.2	124
47	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. <i>Arthritis and Rheumatism</i> , 2007, 56, 2382-2391.	6.7	364
48	The treatment of antiphospholipid syndrome: A harmonic contrast. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 1079-1092.	3.3	18
50	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). <i>Journal of Thrombosis and Haemostasis</i> , 2007, 7, 1183-1188.	2.0	17
51	Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2009, 61, 29-36.	6.7	296
52	New developments in lupus-associated antiphospholipid syndrome. <i>Lupus</i> , 2008, 17, 443-446.	1.6	4
53	Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. <i>Lupus</i> , 2008, 17, 11-15.	1.6	80
54	Novel therapies for the antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 193-203.	3.0	1
55	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008, 17, 271-273.	1.6	63
56	New insights into the management of antiphospholipid syndrome-related thrombosis. <i>Future Rheumatology</i> , 2008, 3, 85-93.	0.2	0
57	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody to $\beta_2$ -glycoprotein I complexes to phospholipid bilayers. <i>Blood</i> , 2008, 112, 1687-1695.	1.4	208

#	ARTICLE	IF	CITATIONS
58	Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 238-241.	0.9	211
59	New approaches for managing antiphospholipid syndrome. <i>Nature Reviews Rheumatology</i> , 2009, 5, 160-170.	8.0	58
60	Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. <i>Platelets</i> , 2009, 20, 367-375.	2.3	23
61	Smoking and atherosclerotic cardiovascular disease: Part II: Role of cigarette smoking in cardiovascular disease development. <i>Biomarkers in Medicine</i> , 2009, 3, 617-653.	1.4	33
62	Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 397-399.	0.9	98
63	Antiphospholipid Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 115-125.	3.1	60
64	Cardiovascular risk assessment and treatment in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 481-494.	3.3	32
65	Thrombotic Microangiopathy and Renal Failure Exacerbated by Îµ-Aminocaproic Acid. <i>American Journal of Kidney Diseases</i> , 2009, 53, 346-350.	1.9	7
66	Venous thromboembolism in pregnancy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 104-113.	0.9	5
67	Catastrophic Antiphospholipid Syndrome Triggered by Sepsis. <i>HSS Journal</i> , 2009, 5, 67-72.	1.7	13
68	Management of the antiphospholipid syndrome: new approaches. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 533-549.	0.3	2
70	Management of antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2009, 33, 92-98.	6.5	70
71	Thrombosis in systemic lupus erythematosus: risk and protection. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1541-1549.	1.5	30
72	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 185-191.	0.1	0
73	Chapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 215-234.	0.1	0
74	Current management of antiphospholipid syndrome-related thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1551-1558.	1.5	9
75	Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 601-614.	1.8	14
76	Pathogenesis and management of antiphospholipid syndrome. <i>Thrombosis Research</i> , 2009, 123, S4-S9.	1.7	3

#	ARTICLE	IF	CITATIONS
77	How we diagnose the antiphospholipid syndrome. <i>Blood</i> , 2009, 113, 985-994.	1.4	167
78	How I treat the antiphospholipid syndrome. <i>Blood</i> , 2009, 114, 2020-2030.	1.4	80
79	Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis. <i>Internal Medicine</i> , 2009, 48, 1875-1880.	0.7	12
80	ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 247-249.	2.5	21
81	Treatment of antiphospholipid antibody syndrome. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 241-254.	0.3	4
82	Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. <i>Blood</i> , 2010, 115, 2292-2299.	1.4	224
83	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2010, 1, 15-22.	3.9	6
84	Thrombosis after a Splenectomy in a Patient with Systemic Lupus Erythematosus-related Thrombocytopenia. <i>The Journal of the Korean Rheumatism Association</i> , 2010, 17, 442.	0.1	0
85	Endocardite de Libman-Sacks, anticorpos antifosfolípidos e trombose arterial no lúpus eritematoso sistêmico: relato de caso. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 716-719.	0.8	2
86	Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. <i>Lupus</i> , 2010, 19, 575-582.	1.6	29
87	Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. <i>Lupus</i> , 2010, 19, 440-445.	1.6	40
88	The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. <i>Lupus</i> , 2010, 19, 460-469.	1.6	127
89	Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?. <i>Lupus</i> , 2010, 19, 475-485.	1.6	56
90	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, s1-s66.	3.6	512
91	A new role for antimalarials in systemic lupus erythematosus treatment. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 299-312.	0.3	2
92	Risk Quantification in Antiphospholipid Syndrome. <i>Women's Health</i> , 2010, 6, 179-182.	1.5	0
93	New therapeutic targets for the antiphospholipid syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1291-1299.	3.4	11
94	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 20-28.	0.9	817

#	ARTICLE	IF	CITATIONS
96	Management of the Antiphospholipid Syndrome. , 2010, , 124-133.		1
97	Antiphospholipid syndrome. Lancet, The, 2010, 376, 1498-1509.	13.7	916
98	Ocular manifestations of the antiphospholipid syndrome. British Journal of Ophthalmology, 2011, 95, 454-459.	3.9	50
99	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus, 2011, 20, 206-218.	1.6	467
100	Treatment of Antiphospholipid Syndrome. , 2011, , 1027-1042.		0
101	Aspirin and Heparin Effect on Basal and Antiphospholipid Antibody Modulation of Trophoblast Function. Obstetrics and Gynecology, 2011, 118, 1021-1028.	2.4	43
102	Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. American Journal of Obstetrics and Gynecology, 2011, 205, 576.e7-576.e14.	1.3	60
103	Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibodyâ€Positive Patients. Current Rheumatology Reports, 2011, 13, 77-80.	4.7	169
104	Primary Thrombosis Prophylaxis in Antiphospholipid Antibodyâ€Positive Patients: Where Do We Stand?. Current Rheumatology Reports, 2011, 13, 59-69.	4.7	66
105	Antiphospholipid syndrome and other lupus-related movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 237-245.	1.8	2
106	Republished review: Ocular manifestations of the antiphospholipid syndrome. Postgraduate Medical Journal, 2011, 87, 496-501.	1.8	3
107	Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus, 2011, 20, 219-224.	1.6	36
108	OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW. Fetal and Maternal Medicine Review, 2011, 22, 265-286.	0.3	0
109	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1083-1086.	0.9	178
111	Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Human Reproduction, 2012, 27, 2933-2940.	0.9	23
112	Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus, 2012, 21, 1506-1514.	1.6	46
113	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2012, 38, 339-347.	2.7	35
114	Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases. Journal of Rheumatology, 2012, 39, 382-388.	2.0	4

#	ARTICLE	IF	CITATIONS
115	Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. <i>Lupus</i> , 2012, 21, 830-835.	1.6	159
116	Thrombosis in Systemic Lupus Erythematosus: A Review Article. <i>ISRN Rheumatology</i> , 2012, 2012, 1-6.	1.9	53
117	Neuropsychiatric Features of a Cohort of Patients with Systemic Lupus Erythematosus. <i>ISRN Rheumatology</i> , 2012, 2012, 1-9.	1.9	15
118	High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. <i>Journal of Clinical Pathology</i> , 2012, 65, 551-556.	2.0	5
119	Prevention of VTE in Nonsurgical Patients. <i>Chest</i> , 2012, 141, e195S-e226S.	0.8	1,780
120	Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. <i>Autoimmunity Reviews</i> , 2012, 12, 289-294.	5.8	12
122	Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 265-274.	6.5	23
123	Cardiovascular Involvement in Systemic Lupus Erythematosus. , 2012, , .		1
124	Hydroxychloroquine: From Malaria to Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 145-153.	6.5	465
125	An unusual presentation of juvenile systemic lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 249-251.	1.3	1
126	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". <i>Autoimmunity Reviews</i> , 2012, 11, 568-571.	5.8	22
127	Antiphospholipid syndrome in obstetrics. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 65-76.	2.8	218
128	Antiphospholipid: to test, or not to test, that is the question. <i>International Journal of Clinical Practice</i> , 2012, 66, 620-621.	1.7	0
129	NEPHROTIC AND ANTI- $\phi$ PHOSPHOLIPID SYNDROMES: MULTISYSTEM CONDITIONS ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION IN YOUNG PATIENTS. <i>Journal of Renal Care</i> , 2012, 38, 9-14.	1.2	4
130	Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy. <i>Micron</i> , 2012, 43, 851-862.	2.2	7
131	Progression of antiphospholipid antibody syndrome to catastrophic antiphospholipid antibody syndrome acutely with cessation of antithrombotic therapy. <i>Internal Medicine Journal</i> , 2012, 42, 585-591.	0.8	5
132	Management of Obstetric Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2012, 14, 79-86.	4.7	30
134	Top 10 Clinical Research Developments in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 367.	4.7	4

#	ARTICLE	IF	CITATIONS
135	Antimalarial Medications. , 2013, , 601-608.		3
136	Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 305-314.	2.7	66
137	Anticoagulation in Management of Antiphospholipid Antibody Syndrome in Pregnancy. Clinics in Laboratory Medicine, 2013, 33, 367-376.	1.4	19
138	Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflammation Research, 2013, 62, 919-927.	4.0	24
139	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2013, 40, 831-841.	2.0	105
140	Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of Î²2-glycoprotein I. Lupus, 2013, 22, 702-711.	1.6	24
141	Perioperative Management of Antiphospholipid Antibody Positive Patients During Noncardiac Surgeries. , 2013, , 91-107.		1
142	Thromboembolism risk following recurrent miscarriage. Expert Review of Cardiovascular Therapy, 2013, 11, 1503-1513.	1.5	2
143	Clinical Aspects of the Antiphospholipid Syndrome. , 2013, , 518-525.		2
144	Special aspects in the treatment of systemic lupus erythematosus. Reumatologia, 2013, 3, 210-214.	1.1	0
145	Renal Infarction in Antiphospholipid Antibody-negative Pediatric Systemic Lupus Erythematosus Patient. Journal of Rheumatic Diseases, 2014, 21, 270.	1.1	0
146	Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety. ISRN Rheumatology, 2014, 2014, 1-13.	1.9	7
147	Effect of Hydroxychloroquine on Antiphospholipid Antibodyâ€Induced Changes in First Trimester Trophoblast Function. American Journal of Reproductive Immunology, 2014, 71, 154-164.	1.2	77
148	Cardiovascular Risk Factors in the Antiphospholipid Syndrome. Journal of Immunology Research, 2014, 2014, 1-6.	2.2	29
150	Perioperative Management of Antiphospholipid Antibody-Positive Patients. Current Rheumatology Reports, 2014, 16, 426.	4.7	25
151	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmunity Reviews, 2014, 13, 281-291.	5.8	166
152	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity Reviews, 2014, 13, 685-696.	5.8	290
153	Immunologic derangement preceding clinical autoimmunity. Lupus, 2014, 23, 1305-1308.	1.6	4

#	ARTICLE	IF	CITATIONS
154	Risk factors for arterial thrombosis in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014, 133, 173-176.	1.7	47
155	Systemic Lupus Erythematosus. <i>Academic Radiology</i> , 2014, 21, 617-623.	2.5	2
156	Antimalarials in Dermatology: Mechanism of Action, Indications, and Side Effects. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 243-252.	0.4	18
157	Prevention and management of co-morbidities in SLE. <i>Presse Medicale</i> , 2014, 43, e187-e195.	1.9	25
158	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches. <i>Journal of Immunology Research</i> , 2015, 2015, 1-20.	2.2	48
159	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 358-362.	5.8	101
160	Postoperative Risk of Venous Thromboembolism in Rheumatic Disease Patients. <i>Current Rheumatology Reports</i> , 2015, 17, 11.	4.7	5
161	A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes. <i>Lupus</i> , 2015, 24, 32-41.	1.6	6
162	Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. <i>Journal of Immunological Methods</i> , 2015, 422, 51-58.	1.4	21
164	Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to Î² 2-Glycoprotein I. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 735-745.	6.1	31
165	Antiphospholipid syndrome: an update. <i>European Journal of Clinical Investigation</i> , 2015, 45, 653-662.	3.4	37
166	The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2016, 3, 75-84.	0.6	141
167	Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1242-1253.	2.0	32
168	Antiphospholipid Syndrome and Kidney Involvement: New Insights. <i>Antibodies</i> , 2016, 5, 17.	2.5	9
169	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , 2016, 5, 9.	5.8	32
171	Prevention of thrombosis in antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 707-713.	2.5	17
172	What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 714-716.	2.5	25
173	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 133-148.	3.3	48

#	ARTICLE	IF	CITATIONS
174	Anti-malarials: Are There Benefits Beyond Mild Disease?. Current Treatment Options in Rheumatology, 2016, 2, 1-12.	1.4	6
175	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. Current Rheumatology Reports, 2016, 18, 26.	4.7	12
176	The diagnosis and management of the haematologic manifestations of lupus. Journal of Autoimmunity, 2016, 74, 139-160.	6.5	94
178	Emerging Therapies in Antiphospholipid Syndrome. Current Rheumatology Reports, 2016, 18, 22.	4.7	37
179	A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmunity Reviews, 2016, 15, 124-138.	5.8	128
180	Anti-phospholipid Antibodies and Smoking: An Overview. Clinical Reviews in Allergy and Immunology, 2017, 53, 1-13.	6.5	20
181	Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2017, , 221-229.	0.1	0
182	Treatment of Thrombosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 231-241.	0.1	0
183	Antiphospholipid Syndrome. Journal of the American College of Cardiology, 2017, 69, 2317-2330.	2.8	109
184	Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting. Lupus, 2017, 26, 1328-1332.	1.6	31
186	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. The Cochrane Library, 0, , .	2.8	4
187	Immunotherapeutic strategies in antiphospholipid syndrome. Internal Medicine Journal, 2017, 47, 250-256.	0.8	4
188	Traditional DMARDs. , 2017, , 958-982.e7.		3
189	Anti-phospholipid Syndrome. , 2017, , 1389-1399.		2
191	Incidence of thromboembolic events in asymptomatic carriers of IgA anti Å2 glycoprotein-I antibodies. PLoS ONE, 2017, 12, e0178889.	2.5	54
192	Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 980-985.	1.7	6
193	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. Journal of Autoimmunity, 2018, 90, 1-27.	6.5	60
194	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. Pharmacological Research, 2018, 133, 108-120.	7.1	7

#	ARTICLE	IF	CITATIONS
195	Pulmonary thromboembolism in patient with coexistence of Behçet's disease and antiphospholipid syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 2188-2192.	1.9	2
196	The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex. <i>Lupus</i> , 2018, 27, 319-326.	1.6	7
197	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 883-889.	3.4	30
198	Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study. <i>Rheumatology International</i> , 2018, 38, 229-238.	3.0	2
199	The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. <i>Oncotarget</i> , 2018, 9, 6615-6622.	1.8	25
201	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	5.8	62
202	Curative resolution of chronic thromboembolic pulmonary hypertension with pulmonary thromboendarterectomy in primary antiphospholipid syndrome. <i>Medicine (United States)</i> , 2018, 97, e12710.	1.0	0
203	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.	4.7	16
204	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
205	The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature. <i>SAGE Open Medical Case Reports</i> , 2018, 6, 2050313X1878280.	0.3	0
206	Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy024.	0.4	6
207	Reimagining the antiphospholipid syndrome, an enigmatic thrombophilic disorder, through the looking glass of microscopic imaging. <i>Histochemistry and Cell Biology</i> , 2018, 150, 529-543.	1.7	3
208	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , 2019, 104, 102311.	6.5	26
210	Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 190-200.	1.4	0
211	The efficacy and safety of antithrombotic therapy in patients with positive antiphospholipid antibodies receiving invasive procedures: experience from a single tertiary center. <i>Clinical Rheumatology</i> , 2019, 38, 1897-1904.	2.2	4
213	Antiphospholipid Syndrome and Renal Allograft Thrombosis. <i>Transplantation</i> , 2019, 103, 481-486.	1.0	14
214	Is there a role for immunosuppression in antiphospholipid syndrome?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 426-432.	2.5	22
215	Antimalarial Medications. , 2019, , 650-660.		0

#	ARTICLE	IF	CITATIONS
216	Contraception and preconception counseling in women with autoimmune disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 11-23.	2.8	8
217	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
218	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000423.	2.7	12
219	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1971-1980.	5.6	51
220	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , 2020, 22, 191.	3.5	21
221	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. <i>New Microbes and New Infections</i> , 2020, 37, 100747.	1.6	17
222	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. <i>The Cochrane Library</i> , 2020, 2020, CD012852.	2.8	47
223	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102491.	5.8	75
224	New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study. <i>Lupus</i> , 2020, 29, 157-164.	1.6	10
225	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020, 32, 215-227.	4.3	8
226	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020, 133, 929-940.	2.3	22
227	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <i>Annals of Medicine</i> , 2021, 53, 117-134.	3.8	58
228	Pulmonary manifestations of systemic lupus erythematosus. , 2021, , 521-529.		0
229	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 37-45.	3.1	5
230	Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome—What is the evidence?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1174-1185.	3.8	14
231	Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2021, 8, e000472.	2.7	6
232	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 997-1004.	5.6	32
233	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021, 30, 1790-1798.	1.6	1

#	ARTICLE	IF	CITATIONS
235	Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. Arthritis and Rheumatology, 2021, 73, 1780-1790.	5.6	16
236	Antimalarial drugs (and lupus). , 2021, , 601-609.		0
237	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. Biomedicines, 2021, 9, 122.	3.2	5
238	Heart Disease, Pregnancy and Systemic Autoimmune Diseases. , 0, , 136-150.		3
239	Management of Thrombosis in Antiphospholipid Syndrome. , 2006, , 547-554.		4
240	Task Force Report on Antiphospholipid Syndrome Clinical Research. , 2012, , 247-257.		7
241	HEMATOLOGY: COAGULATION PROBLEMS. , 2004, , 1139-1160.		1
243	Management of the Difficult Aspects of the Antiphospholipid Syndrome. , 2002, , 395-407.		2
244	Traditional DMARDs. , 2013, , 917-940.e6.		2
245	The Antiphospholipid Syndrome: Clinical Presentation, Diagnosis, and Patient Management. , 2007, , 319-338.		2
246	Catastrophic cerebral antiphospholipid syndrome presenting as cerebral infarction with haemorrhagic transformation after sudden withdrawal of warfarin in a patient with primary antiphospholipid syndrome. BMJ Case Reports, 2010, 2010, bcr0920092243-bcr0920092243.	0.5	5
247	Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study. Current Rheumatology Reviews, 2018, 15, 59-66.	0.8	5
248	Antiphospholipid Syndrome (APS) - An Update on Clinical Features and Treatment Options. The Open Urology & Nephrology Journal, 2015, 8, 27-38.	0.2	1
249	Antiphospholipid syndrome: treatment controversies. Future Rheumatology, 2006, 1, 345-353.	0.2	3
250	Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. World Journal of Gastroenterology, 2013, 19, 6494.	3.3	7
254	ANTIMALARIAL DRUGS IN THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS: PAST, PRESENT, FUTURE. Sovremennaya Revmatologiya, 2010, .	0.5	0
255	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. , 2011, , 17-25.		0
257	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1

#	ARTICLE	IF	CITATIONS
258	What are the Potential Future Treatments in Antiphospholipid Syndrome?. , 2012, , 261-287.		0
259	Antiphospholipid Syndrome and Venous Thrombosis. , 0, , .		0
260	How to Avoid Delay in SLE Diagnosis and Management. , 0, , .		3
261	Atherogenesis and Vascular Disease in SLE. , 0, , .		0
262	Antiphospholipid Syndrome - An Evolving Story of a Multisystemic Disease. , 0, , .		0
264	Neuropsychiatric damage in Systemic Lupus Erythematosus: Possible protective role of medications.. Revista De Neuro-psiquiatria, 2013, 71, 51-57.	0.2	0
267	The Catastrophic Antiphospholipid Antibody Syndrome: An Unusual Presentation of Spontaneous Acute Intracranial Haemorrhage. Journal of Neurology & Stroke, 2015, 3, .	0.1	0
268	TEG-Platelet Mapping-Guided Evaluation of Anti-Phospholipid Carrier with Unusual Clinical Presentation and Paradoxical Laboratory Findings. Hematology & Transfusion International Journal, 2016, 2, .	0.1	0
269	Antiphospholipid Antibodies and Syndrome: Complexities in Diagnosis and Management. , 2016, , 485-494.		0
270	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
271	Antiphospholipid Syndrome: Clinical Features and Genetics of Thrombotic Manifestations. Ukraïns'kij Źurnal Medicini BĀologĀ Ta Sportu, 2017, 2, 161-167.	0.2	0
272	An unusual case of heart attack. Hong Kong Bulletin on Rheumatic Diseases, 2018, 18, 7-13.	0.1	0
273	A case of antiphospholipid syndrome with progression of intracranial artery lesion difficult to treatment. Nosotchu, 2020, 42, 400-405.	0.1	0
274	Renal Manifestations in Lupus Pregnancy. , 2020, , 61-76.		0
275	Primary Anti-phospholipid Antibody Syndrome Presenting as Acute Nephritic Syndrome. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2020, 31, 860.	0.3	0
276	Antiphospholipid syndrome: an overview. Cmaj, 2003, 168, 1675-82.	2.0	27
277	Antiphospholipid Syndrome during pregnancy: the state of the art. Journal of Prenatal Medicine, 2011, 5, 41-53.	0.2	58
278	AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score. Journal of Atrial Fibrillation, 2012, 5, 649.	0.5	14

#	ARTICLE	IF	CITATIONS
279	Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients. <i>Chinese Medical Journal</i> , 2022, 135, 658-664.	2.3	8
280	An Update on Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2021, 23, 84.	4.7	20
281	Antiphospholipid Syndrome and Stroke. , 0, , .		0
283	Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1331.	4.1	6
284	Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study. <i>Rheumatology and Therapy</i> , 2023, 10, 649-658.	2.3	0
285	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. <i>BMJ, The</i> , 0, , e069717.	6.0	33
286	An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 617.	4.0	1
287	Controversies in the Management of Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , 2023, 29, e107-e112.	0.9	1
288	Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre. <i>Journal of Clinical Medicine</i> , 2023, 12, 2996.	2.4	3
289	Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort. <i>RMD Open</i> , 2023, 9, e003084.	3.8	0
291	Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study. <i>Rheumatology</i> , 0, , .	1.9	0
292	Association of anti-Î²2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	1
293	Non-invasive imaging in antiphospholipid syndrome to assess subclinical coronary artery disease. <i>Autoimmunity Reviews</i> , 2024, 23, 103505.	5.8	0
294	Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. <i>Autoimmunity Reviews</i> , 2024, 23, 103510.	5.8	1
295	Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis. <i>Vessel Plus</i> , 0, , .	0.4	0